Addressing Current Dilemmas in Stroke Prevention: Challenges in Risk-Specific Intervention for AF—“Taking the Pulse” for Year 2010 and Beyond Samuel Z. Goldhaber, MD
Assessing Stroke Risk in AF: Aligning Available and Investigational Therapies with Appropriate Patient Subgroups with Chronic AF Jonathan L. Halperin, MD
From Risk to Remedy: The Role of Direct Thrombin and Factor Xa Inhibition for Stroke Prevention in Atrial Fibrillation—Mechanisms, Rationale, and Applications Across the Variable Risk Spectrum for AF Jeffrey I. Weitz, MD, FRCP, FACP
Optimizing Stroke Prevention in AF with Established, Currently Available Therapies: The Role of Vitamin K Antagonists—What Works? What Doesn’t? In Whom and When? David A. Garcia, MD
So What Now? Applying Remedies to Risk Groups in the Real World Setting for SPAF Elaine M. Hylek, MD, MPH
Deciphering the Maze: What Have the Trials Told Us? And What Will SPAF Look Like for Cardiologists at the Front Lines of Clinical Practice? Samuel Z. Goldhaber, MD
Interactive Question and Answer Session Faculty Panel
